部份中文考来替兰处方资料（仅供参考）
商品名：BindRen
英文名：Colestilan
中文名：考来替兰颗粒
生产商：Mitsubishi Tanabe Pharma GmbH
药理作用
本品可影响胆汁酸以及胆固醇的吸收。其作用机制为在消化道内吸附胆汁酸，抑制胆汁酸和胆固醇的再吸收，从而促进胆汁酸以及胆固醇的排泄，并增加肝内UDL受体促使血中LDL进入肝脏，从而也降低血中LDL。
适应症：
1.慢性肾病第五期接受腹膜透析或者血液透析的成人患者的高磷酸血症（2013年1月欧盟批准）(1g)
2.高胆固醇血症（500mg）
用法用量：
首剂量是每天6 -9克(分2-3次服用)。
制剂规格：
薄膜衣片：1g/片；
颗粒：2g/袋，3g/袋； 
BindRen: new phosphate binder
BindRen (colestilan) has been launched for the treatment of hyperphosphataemia in patient with stage 5 chronic kidney disease who are currently receiving dialysis.
PHARMACOLOGY
Colestilan is an anion exchange resin. It binds to phosphate in the gut but is not absorbed from the gastrointestinal tract, thereby increasing phosphate excretion. As colestilan may affect the bioavailability or absorption of other medicinal products, these should be taken at least 1 hour before or 3 hours after colestilan.1
CLINICAL STUDIES
Investigators assessed colestilan in three key placebo-controlled, phase III studies: two open-label flexible-dose studies in which they adjusted the colestilan dose according to phosphate levels and one fixed-dose study in which they randomised patients to receive 3g, 6g, 9g, 12g or 15g of colestilan per day or placebo.1,2
Significant phosphate lowering
In all studies, colestilan at a dose of at least 6g daily resulted in a significantly reduced blood phosphate level after 12 weeks of treatment compared with placebo. An average dose of 11.5g and 13.1g daily in the first and second flexible-dose studies reduced the blood phosphate level by 0.36mmol and 0.50mmol per litre, respectively.1,2
In the fixed-dose study, significant changes in blood phosphate levels were observed for patients who received at least 6g of colestilan daily compared with placebo. These changes were dose dependent.1,2
GI upset
Most adverse events in trials were gastrointestinal in origin, including nausea, vomiting, dyspepsia, constipation and haemorrhage.1,2
---------------------------------------------------
附件:
201412723561833.pdf